AbbVie Inc. (NYSE:ABBV) is listed among the 14 Best Pharma Dividend Stocks to Buy in 2026. BofA lowered AbbVie’s price target to $233 from $248 while maintaining a Neutral rating, citing limited late-stage pipeline catalysts and premium valuation. The stock has risen over 28% since 2025, with solid financial performance.

AbbVie expects momentum to continue into 2026 and beyond, with high single-digit revenue growth forecasted through 2029. Sales estimates for immunology drugs Skyrizi and Rinvoq have been raised by $4 billion. Oncology revenue is also projected to increase next year, supporting overall growth.

AbbVie Inc. is a global biopharmaceutical company focusing on innovative medicines for serious health conditions. While AbbVie presents investment potential, some believe certain AI stocks offer greater upside with less downside risk. A free report on the best short-term AI stock is available for those interested.

Disclosure: None.

Read more at Yahoo Finance: BofA Cuts AbbVie (ABBV) Target While Maintaining Neutral View